other material
confidence high
sentiment positive
materiality 0.85
Novocure METIS Phase 3 trial meets primary endpoint; intracranial progression delay 21.9 vs 11.3 months
NovoCure Ltd
- TTFields + supportive care showed median time to intracranial progression of 21.9 months vs 11.3 months for supportive care alone (HR=0.67, p=0.016).
- Key secondary endpoints (neurocognitive failure, overall survival, radiological response) did not reach statistical significance.
- Median TTFields therapy duration was 16 weeks, median usage 67%; therapy well-tolerated with sustained quality of life.
- Novocure plans to submit data to regulatory authorities and publish findings in a peer-reviewed journal.
- Phase 3 METIS trial enrolled 298 patients with 1-10 brain metastases from NSCLC following stereotactic radiosurgery.